Drug Research
Phesi Big Data Analysis of Over 200,000 Hepatitis B and C Patients Identifies Typical Patient to Help Drive Forward Disease Elimination Goals
Phesi Inc., a data-driven provider of AI-powered clinical development analytics products and solutions, has analyzed data from 209,860 hepatitis B (HBV) and C (HCV) patients, from 940 trial arms/cohorts to build a picture of the “typical” patient and identify...
Drug Research
Sanofi to focus its COVID-19 development efforts on the recombinant vaccine candidate
Recent positive interim results of Sanofi’s mRNA-based COVID-19 vaccine candidate Phase 1/2 study confirm the company’s platform robust capabilities and strategy in mRNA.
Taking into account public health needs and given sufficient mRNA COVID-19 vaccines supply can be expected going...
Drug Research
Syndax and Incyte Announce Global Collaboration to Develop and Commercialize Axatilimab for Chronic Graft-Versus-Host Disease and Other Fibrotic Diseases
Syndax Pharmaceuticals, Inc. and Incyte announced that they have entered into an exclusive worldwide collaboration and license agreement to develop and commercialize axatilimab, Syndax’s anti-CSF-1R monoclonal antibody.
“This partnership has the potential to significantly expand and maximize the axatilimab program...
Drug Research
Union therapeutics signs deal with Innovent to develop orismilast in China
Union therapeutics has signed a strategic partnership and license agreement with Innovent Biologics to develop and commercialise its therapy, orismilast, in China.
A potent and selective next-generation PDE4 inhibitor for inflammatory dermatology conditions, orismilast possesses extensive anti-inflammatory properties.
Developed originally by...
Drug Research
InSilicoTrials and Galileo Research announce their partnership
Innovation and cutting-edge technology to reduce Research and Development time and costs: InSilicoTrials, a company with broad expertise in Computational Modeling and Simulation, IT and cloud solutions for the healthcare sector, and Galileo Research established a partnership to apply...
Drug Research
Velocity Clinical Research’s multi-site acquisitions signal new frontier for clinical site management industry
Velocity Clinical Research announces it has acquired two multi-site companies, VitaLink Research and the National Research Institute, for an undisclosed amount. The double acquisition adds 11 sites to Velocity’s existing 18, making it the largest fully integrated site management...
Drug Research
FDA Approves Samsung Bioepis and Biogens BYOOVIZ, LUCENTIS Biosimilar
Samsung Bioepis Co., Ltd. and Biogen Inc. announced that the U.S. FDA has approved BYOOVIZ (ranibizumab-nuna), a biosimilar referencing LUCENTIS® (ranibizumab)i , for the treatment of neovascular (wet) age-related macular degeneration (AMD), macular edema following retinal vein occlusion (RVO),...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read
